Targeting of interleukin-13 receptor α2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF-β and PTEN signaling

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Hall, Bradford ^a   Nakashima, Hideyuki ^b   Sun, Zhi Jun ^a   Sato, Yuki ^b   Bian, Yansong ^a,c   Husain, Syed R ^b   Puri, Raj K ^b   Kulkarni, Ashok B ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

Author keywords

HNSCC; IL 13 receptor; Immunotoxin; PTEN; TGF

Indexed keywords

HYBRID PROTEIN; INTERLEUKIN 13 PSEUDOMONAS EXOTOXIN A FUSION PROTEIN; INTERLEUKIN 13 RECEPTOR ALPHA2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE DELETION; GENE OVEREXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PHOSPHATASE AND TENSIN HOMOLOG GENE; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; SURVIVAL TIME; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1 GENE; TUMOR CELL; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MICE; MICE, KNOCKOUT; PROTEIN-SERINE-THREONINE KINASES; PTEN PHOSPHOHYDROLASE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84873980242     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-45     Document Type: Article

References (31)

1. Bian Y, Hall B, Sun ZJ, Molinolo A, Chen W, Gutkind JS, Waes CV, Kulkarni AB. Loss of TGF-β signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene 2011, 31:3322-32.
2. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 2009, 45:324-34. 10.1016/j.oraloncology.2008.07.011, 2743485, 18805044.
3. Eisma RJ, Spiro JD, von Biberstein SE, Lindquist R, Kreutzer DL. Decreased expression of transforming growth factor beta receptors on head and neck squamous cell carcinoma tumor cells. Am J Surg 1996, 172:641-5. 10.1016/S0002-9610(96)00305-4, 8988667.
4. Fukai Y, Fukuchi M, Masuda N, Osawa H, Kato H, Nakajima T, Kuwano H. Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma. Int J Cancer 2003, 104:161-6. 10.1002/ijc.10929, 12569570.
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
6. Bauman JE, Michel LS, Chung CH. New promising molecular targets in head and neck squamous cell carcinoma. Curr Opin Oncol 2012, 24:235-42. 10.1097/CCO.0b013e3283517920, 22327839.
7. Kawakami M, Kawakami K, Kasperbauer JL, Hinkley LL, Tsukuda M, Strome SE, Puri RK. Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin Cancer Res 2003, 9:6381-8.
8. Debinski W, Gibo DM. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med 2000, 6:440-9. 1949955, 10952023.
9. Joshi BH, Puri RK. Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli. Protein Expr Purif 2005, 39:189. 10.1016/j.pep.2004.10.012, 15642470.
10. Kawakami K, Kawakami M, Joshi BH, Puri RK. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res 2001, 61:6194-200.
11. Fichtner-Feigl S, Terabe M, Kitani A, Young CA, Fuss I, Geissler EK, Schlitt HJ, Berzofsky JA, Strober W. Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res 2008, 68:3467-75. 10.1158/0008-5472.CAN-07-5301, 2746996, 18451175.
12. Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B, Letterio JJ, Paul WE, Berzofsky JA. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003, 198:1741-52. 10.1084/jem.20022227, 2194133, 14657224.
13. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006, 12:99-106. 10.1038/nm1332, 16327802.
14. MacDonald TT. Decoy receptor springs to life and eases fibrosis. Nat Med 2006, 12:13-4. 10.1038/nm0106-13, 16397542.
15. Zurawski SM, Vega F, Huyghe B, Zurawski G. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J 1993, 12:2663-2670. 413514, 8101483.
16. Honjo Y, Bian Y, Kawakami K, Molinolo A, Longenecker G, Boppana R, Larsson J, Karlsson S, Gutkind JS, Puri RK, Kulkarni AB. TGF-beta receptor I conditional knockout mice develop spontaneous squamous cell carcinoma. Cell Cycle 2007, 6:1360-6. 10.4161/cc.6.11.4268, 17534148.
17. Nakashima H, Terabe M, Berzofsky JA, Husain SR, Puri RK. A novel combination immunotherapy for cancer by IL-13Rα2-targeted DNA vaccine and immunotoxin in murine tumor models. J Immunol 2011, 187:4935-46. 10.4049/jimmunol.1102095, 22013118.
18. Kawakami K, Taguchi J, Murata T, Puri RK. The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 2001, 97:2673-9. 10.1182/blood.V97.9.2673, 11313257.
19. Kioi M, Kawakami K, Puri RK. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin. Clin Cancer Res 2004, 10:6231-8. 10.1158/1078-0432.CCR-04-0700, 15448012.
20. Nakashima H, Fujisawa T, Husain SR, Puri RK. Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models. J Transl Med 2010, 8:116. 10.1186/1479-5876-8-116, 2993653, 21067607.
21. Puri RK, Leland P, Obiri NI, Husain SR, Kreitman RJ, Haas GP, Pastan I, Debinski W. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 1996, 87:4333-9.
22. Husain SR, Joshi BH, Puri RK. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 2001, 92:168-175. 10.1002/1097-0215(200102)9999:9999<::AID-IJC1182>3.0.CO;2-N, 11291041.
23. Kawakami K, Husain SR, Kawakami M, Puri RK. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model. Mol Med 2002, 8:487-94. 2040009, 12435859.
24. Kawakami K, Kawakami M, Husain SR, Puri RK. Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor α2 chain in vivo. Gene Ther 2003, 10:1116-28. 10.1038/sj.gt.3301956, 12808442.
25. Joshi BH, Kawakami K, Leland P, Puri RK. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res 2002, 8:1948-56.
26. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007, 58:221-37. 10.1146/annurev.med.58.070605.115320, 17059365.
27. Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 2003, 65:37-48. 10.1023/A:1026242432647, 14649884.
28. Fujisawa T, Joshi BH, Miyajima A, Puri RK. A novel role of interleukin-13 receptor α2 in pancreatic cancer invasion and metstasis. Cancer Res 2009, 69:8678-85. 10.1158/0008-5472.CAN-09-2100, 19887609.
29. Kioi M, Shimamura T, Nakashima H, Hirota M, Tohnai I, Husain SR, Puri RK. IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma. Int J Cancer 2009, 124:1440-8. 10.1002/ijc.24067, 19065664.
30. Fujisawa T, Nakashima H, Nakajima A, Joshi BH, Puri RK. Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine. Int J Cancer 2011, 128:1221-31. 10.1002/ijc.25437, 20473925.
31. Sun ZJ, Zhang L, Hall B, Bian Y, Gutkind JS, Kulkarni AB. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically-defined head and neck squamous cell carcinoma mouse model. Clin Cancer Res 2012, 18:5304-13. 10.1158/1078-0432.CCR-12-1371, 22859719.